MARAVAI LIFESCIENCES HOLDINGS, INC. Financials Maravai LifeSciences Holdings, Inc.
Equities
MRVI
US56600D1072
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.7 USD | +1.58% |
|
+5.48% | +17.56% |
| Apr. 18 | Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego | MT |
| Apr. 10 | Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,748 | 5,508 | 1,882 | 865.8 | 1,021 | - | - |
| Enterprise Value (EV) 1 | 3,103 | 5,487 | 1,778 | 865.8 | 1,009 | 928.1 | 749.6 |
| P/E ratio | 81.2 x | 26.9 x | 8.57 x | -7.28 x | -75.6 x | -150 x | 1,048 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.67 x | 6.89 x | 2.13 x | 3 x | 3.75 x | 3.4 x | 2.95 x |
| EV / Revenue | 10.9 x | 6.87 x | 2.01 x | 3 x | 3.7 x | 3.09 x | 2.17 x |
| EV / EBITDA | 18.3 x | 9.42 x | 2.79 x | 13.3 x | 16.3 x | 11.6 x | 7.39 x |
| EV / FCF | 24.5 x | 15.5 x | 3.43 x | - | 22.8 x | 13 x | 7.35 x |
| FCF Yield | 4.09% | 6.45% | 29.2% | - | 4.38% | 7.7% | 13.6% |
| Price to Book | 133 x | 33.8 x | 6.7 x | - | 1.8 x | 1.74 x | 1.65 x |
| Nbr of stocks (in thousands) | 97,966 | 131,459 | 131,540 | 132,189 | 132,655 | - | - |
| Reference price 2 | 28.05 | 41.90 | 14.31 | 6.550 | 7.700 | 7.700 | 7.700 |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 284.1 | 799.2 | 883 | 288.9 | 272.3 | 300.5 | 346 |
| EBITDA 1 | 169.2 | 582.8 | 637.8 | 65.31 | 62.05 | 80.29 | 101.4 |
| EBIT 1 | 143.3 | 558.1 | 606 | 25.06 | 20.4 | 39.61 | 72.04 |
| Operating Margin | 50.42% | 69.82% | 68.63% | 8.67% | 7.49% | 13.18% | 20.82% |
| Earnings before Tax (EBT) 1 | 81.7 | 530.8 | 551.5 | 617.7 | -32.67 | -10.92 | 7.132 |
| Net income 1 | 88.97 | 182 | 220.2 | -119 | -13.46 | -1.639 | 6.27 |
| Net margin | 31.32% | 22.78% | 24.94% | -41.19% | -4.94% | -0.55% | 1.81% |
| EPS 2 | 0.3454 | 1.560 | 1.670 | -0.9000 | -0.1018 | -0.0514 | 0.007350 |
| Free Cash Flow 1 | 126.8 | 353.7 | 518.9 | - | 44.21 | 71.47 | 102 |
| FCF margin | 44.63% | 44.26% | 58.76% | - | 16.23% | 23.78% | 29.48% |
| FCF Conversion (EBITDA) | 74.94% | 60.69% | 81.36% | - | 71.25% | 89.01% | 100.62% |
| FCF Conversion (Net income) | 142.49% | 194.31% | 235.64% | - | - | - | 1,626.66% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 204.8 | 228.4 | 244.3 | 242.7 | 191.3 | 204.7 | 79.02 | 68.91 | 66.86 | 74.14 | 60.55 | 66.81 | 69.7 | 74.4 | 68.61 |
| EBITDA 1 | 156 | 162.7 | 187 | 188.5 | 132.5 | 129.8 | 23.8 | 9.077 | 11.9 | 20.53 | 8.926 | 14.87 | 16.74 | 20.77 | 15.33 |
| EBIT 1 | 148.9 | 157.3 | 179.6 | 180.3 | 124.4 | 121.6 | 14.95 | -0.59 | 0.959 | 9.733 | -2.1 | 3.775 | 6.825 | 11.35 | 8.1 |
| Operating Margin | 72.71% | 68.85% | 73.52% | 74.29% | 65.04% | 59.41% | 18.92% | -0.86% | 1.43% | 13.13% | -3.47% | 5.65% | 9.79% | 15.25% | 11.81% |
| Earnings before Tax (EBT) 1 | 151.7 | 144.7 | 166.8 | 175 | 113.8 | 95.88 | -4.523 | -13.36 | -20.56 | 656.2 | -14.91 | -9.394 | -7.393 | -3.398 | 1.242 |
| Net income 1 | 54.27 | 55.83 | 66.86 | 71.24 | 44.47 | 37.63 | -0.067 | -6.541 | -6.462 | -106 | -8.014 | -5.246 | -3.67 | -1.08 | -0.9242 |
| Net margin | 26.5% | 24.44% | 27.37% | 29.35% | 23.25% | 18.38% | -0.08% | -9.49% | -9.66% | -142.92% | -13.24% | -7.85% | -5.27% | -1.45% | -1.35% |
| EPS 2 | 0.4500 | 0.4200 | 0.5000 | 0.5300 | 0.3400 | 0.2800 | - | -0.0500 | -0.0500 | -0.8000 | -0.0486 | -0.0350 | -0.0270 | -0.003550 | 0.0213 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/23/22 | 5/5/22 | 8/4/22 | 11/2/22 | 2/22/23 | 5/8/23 | 8/7/23 | 11/7/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 355 | - | - | - | - | - | - |
| Net Cash position 1 | - | 20.7 | 105 | - | 12.6 | 93.3 | 272 |
| Leverage (Debt/EBITDA) | 2.096 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 127 | 354 | 519 | - | 44.2 | 71.5 | 102 |
| ROE (net income / shareholders' equity) | 77.4% | 90.1% | 51.2% | - | 1.78% | 2.73% | 2.37% |
| ROA (Net income/ Total Assets) | 9.63% | 11.4% | 10.5% | - | -0.48% | -0.32% | -0.02% |
| Assets 1 | 924.2 | 1,594 | 2,100 | - | 2,794 | 505 | -31,166 |
| Book Value Per Share 2 | 0.2100 | 1.240 | 2.140 | - | 4.290 | 4.440 | 4.670 |
| Cash Flow per Share 2 | 5.260 | 1.430 | 2.100 | - | 0.2400 | 0.6900 | 0.5800 |
| Capex 1 | 25.4 | 14.9 | 17.1 | - | 32.7 | 23.3 | 22.5 |
| Capex / Sales | 8.94% | 1.86% | 1.94% | - | 11.99% | 7.77% | 6.51% |
| Announcement Date | 3/2/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
7.7
USD
Average target price
9.785
USD
Spread / Average Target
+27.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.56% | 1.02B | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M | |
| +13.32% | 332M |
- Stock Market
- Equities
- MRVI Stock
- Financials Maravai LifeSciences Holdings, Inc.
